Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 930Neoplasms 708Prostatic Neoplasms 490Lung Neoplasms 398Carcinoma, Non-Small-Cell Lung 359Colorectal Neoplasms 357Leukemia, Myeloid, Acute 290Pancreatic Neoplasms 238Brain Neoplasms 227Neoplasm Metastasis 221Multiple Myeloma 214Carcinoma, Hepatocellular 199Head and Neck Neoplasms 182Glioblastoma 181Precursor Cell Lymphoblastic Leukemia-Lymphoma 177Melanoma 173Ovarian Neoplasms 168Squamous Cell Carcinoma of Head and Neck 160Uterine Cervical Neoplasms 144Rectal Neoplasms 144Recurrence 142Hematologic Neoplasms 134Sarcoma 133Triple Negative Breast Neoplasms 127Stomach Neoplasms 127Glioma 126Carcinoma, Renal Cell 123Colonic Neoplasms 113Myelodysplastic Syndromes 112Urinary Bladder Neoplasms 109

Interventions

olaparib 1decitabine and cedazuridine drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × BRCA1 Mutation × 90 days × Clear all
NCT06177171 2026-05-27

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

University of California, San Francisco

Phase 1 Recruiting
18 enrolled

BRCA1 Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡